Skin Cancer Connect - April 2024 

Expert consensus panel report recommends DecisionDx-SCC

The panel's unanimous adoption of consensus statements and recommendations of Castle Biosciences' DecisionDx-SCC prognostic test is the focal point of the article. A distinguished panel of eight dermatologists with specialized expertise in the diagnosis and management of squamous cell carcinoma, convened to analyze 21 pertinent articles on the utilization of gene expression profiling (GEP) testing for assessing risk of metastasis in cSCC.

Visit with us at:

Real World Dermatology for Residents Conference

  • April 18-20
  • Las Vegas, NV

Spring JADPRO Insights Forum

  • April 19-20
  • New Orleans, LA

ACMS 56th Annual Meeting

  • May 2-5
  • Phoenix, AZ

2024 Fall Clinical Dermatology Conference for PAs & NPs

  • May 31-June 2
  • Scottsdale, AZ